Summary
Eugene Schneider, Ionis Pharmaceuticals' executive vice president and chief clinical development officer, completed a sale of 5,812 shares of the company's common stock on March 19, 2026, for approximately $412,486. The transactions were reported on a Form 4 filed with the Securities and Exchange Commission and were executed at prices between $70.76 and $71.375. Following the sale, Schneider retained direct ownership of 63,890 shares.
Transaction details
The insider sale was carried out under a pre-established Rule 10b5-1 trading plan that Schneider adopted on November 19, 2025. The publicly disclosed filing documents the quantity sold, the date of sale, and the execution price range. As of the latest quote, Ionis stock trades at $70.79, which the company notes is down 10.5% year-to-date while having posted a 115% gain over the prior 12 months.
Regulatory and clinical developments
Ionis is progressing several regulatory dossiers and clinical readouts. The U.S. Food and Drug Administration has accepted the New Drug Application for zilganersen, a candidate for Alexander disease, and granted it Priority Review with a target action date of September 22, 2026. Separately, the FDA accepted a supplemental New Drug Application for olezarsen for severe hypertriglyceridemia, also placing that submission under Priority Review with a target action date of June 30, 2026. In addition, new data for DAWNZERA, an RNA-targeted therapy for hereditary angioedema, will be presented at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting.
Analyst reactions and company outlook
Market analysts have adjusted their price targets following the company's fourth-quarter 2025 update and 2026 guidance. Bernstein SocGen Group raised its target to $90 while keeping a Market Perform rating, citing what it described as de-risking ahead of a catalyst-rich second half of 2026. Stifel increased its target to $77 from $73 and maintained a Hold rating after the company provided 2026 topline guidance that was below Street expectations. These analyst moves come amid the set of regulatory milestones and upcoming clinical presentations.
Context and implications
The reported insider sale, timed under a 10b5-1 plan, coincides with a period of concentrated regulatory activity for Ionis. The company faces two Priority Review action dates this year and has a scheduled data presentation at a major medical meeting. At the same time, recent guidance did not meet Street expectations, prompting adjustments to analyst price targets and ratings. The combination of insider activity, pending regulatory decisions, and market reaction to guidance contributes to a dynamic near-term outlook for the company.
What is known and what is not
All facts above are drawn from the SEC filing and the company's reported regulatory filings and analyst commentary. Information is limited to the disclosed sale details, the stated ownership post-transaction, the existence and adoption date of the 10b5-1 plan, the FDA acceptance and Priority Review designations with their target dates, the planned DAWNZERA presentation, analyst price-target changes and ratings, and the company's 2026 topline guidance relative to Street expectations.